Breaking News, Collaborations & Alliances

Secarna, SciNeuro Enter Research Agreement for CNS Diseases

Secarna will employ its commercially validated locked nucleic acid discovery and development platform, LNAplus.

Secarna Pharmaceuticals GmbH & Co. KG, a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets, and SciNeuro Pharmaceuticals, a company involved in the discovery and development of innovative therapeutics for the treatment of neurological diseases, entered a multi-target research and option agreement. The companies will work together to generate novel ASO the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters